April 25, 2019
Novartis agreed Thursday to settle its D.C. federal lawsuit that accused Janssen of touting skewed study results to make it seem like Janssen's plaque psoriasis treatment, Tremfya, is less dangerous and more effective than Novartis' own Cosentyx.
March 06, 2019
Novartis Pharmaceuticals Corp. has asked a D.C. federal court to force Janssen Pharmaceuticals Inc. to stop touting skewed study results that make it seem like Janssen’s plaque psoriasis treatment, Tremfya, is less dangerous and more effective than Novartis’ own Cosentyx. (Correction: A previous version of this article misstated Novartis' allegations. The error has been corrected.)
March 01, 2019
Novartis Pharmaceuticals Corp. hit a Johnson & Johnson subsidiary with a false advertising suit in D.C. federal court Friday, saying the company is wrongly claiming its drug to treat plaque psoriasis, Tremfya, is better than the Novartis version, Cosentyx, at conferences.